Sofinnova Investments’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Sofinnova Investments’s Portfolio GRTX Stock Details GRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,083,712	Closed	-$448K	–	89
2023 Q4	$448K	Hold	3,083,712	–	–	0.03%	56
2023 Q3	$540K	Hold	3,083,712	–	–	0.03%	60
2023 Q2	$9.62M	Hold	3,083,712	–	–	0.63%	32
2023 Q1	$7.89M	Hold	3,083,712	–	–	0.5%	35
2022 Q4	$4.59M	Hold	3,083,712	–	–	0.27%	38
2022 Q3	$5.37M	Hold	3,083,712	–	–	0.31%	44
2022 Q2	$4.01M	Hold	3,083,712	–	–	0.33%	46
2022 Q1	$7.34M	Hold	3,083,712	–	–	0.56%	37
2021 Q4	$14.2M	Hold	3,083,712	–	–	0.83%	30
2021 Q3	$25M	Hold	3,083,712	–	–	1.48%	13
2021 Q2	$30.3M	Hold	3,083,712	–	–	1.75%	13
2021 Q1	$27.2M	Hold	3,083,712	–	–	1.64%	15
2020 Q4	$31.5M	Hold	3,083,712	–	–	1.88%	12
2020 Q3	$27.9M	Hold	3,083,712	–	–	2.07%	13
2020 Q2	$22M	Hold	3,083,712	–	–	1.39%	20
2020 Q1	$29.3M	Hold	3,083,712	–	–	2.71%	9
2019 Q4	$40.6M	Buy	+3,083,712	New	+$37.6M	2.93%	8

Other funds holding GRTX

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Atom Investors Austin, Texas $1.12B AUM 38.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Sofinnova Investments's GRTX Position: Q1 2024 in Review

Sofinnova Investments sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2024, closing a stake of 3,083,712 shares — an estimated $448K sold.

Sofinnova Investments first reported a position in GRTX in Q4 2019 and held it in 17 quarters. The position peaked at $40.6M in Q4 2019. 36 funds tracked by Wall St. Rank hold GRTX as of Q1 2024.

Sofinnova Investments reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Sofinnova Investments sold 3,083,712 Galera Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $448K.
Sofinnova Investments first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
Sofinnova Investments's Galera Therapeutics, Inc. Common Stock position peaked at $40.6M in Q4 2019.
36 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.